Roche receives FDA approval of label expansion for VENTANA PD-L1 (SP263) Assay to identify patients with locally advanced and metastatic non-small cell lung cancer eligible for Libtayo

/PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has approved the VENTANA PD-L1 (SP263)...

Related Keywords

Germany ,Japan ,United States ,Switzerland ,German ,Jo Lynn Garing ,Genentech ,World Health Organization ,Drug Administration ,Roche Molecular Systems Inc ,Head Of Pathology Lab ,Roche Diagnostics Communications ,Roche Group ,Jill German ,Pathology Lab ,Dow Jones Sustainability Indices ,Chugai Pharmaceutical ,Ocast Report ,Health Organization ,Lung Cancer ,Roche Diagnostics ,Lynn Garing ,Molecular Systems ,Roche Molecular Systems ,Nc ,Health Care Amp Hospitals ,Medical Pharmaceuticals ,Otc ,Mallcap ,Biotechnology ,Fda Approval ,